{"organizations": [], "uuid": "acb52f50bdb667dff4979d4f7ac3863a45731b1e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/12/business-wire-illumina-names-dr-phil-febbo-chief-medical-officer.html", "country": "US", "domain_rank": 767, "title": "Illumina Names Dr. Phil Febbo Chief Medical Officer", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.37, "site_type": "news", "published": "2018-03-12T23:05:00.000+02:00", "replies_count": 0, "uuid": "acb52f50bdb667dff4979d4f7ac3863a45731b1e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/12/business-wire-illumina-names-dr-phil-febbo-chief-medical-officer.html", "ord_in_thread": 0, "title": "Illumina Names Dr. Phil Febbo Chief Medical Officer", "locations": [], "entities": {"persons": [{"name": "phil febbo", "sentiment": "negative"}, {"name": "garret hampton", "sentiment": "none"}, {"name": "febbo", "sentiment": "none"}, {"name": "phil", "sentiment": "none"}], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "illumina", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "illumina, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Brings unmatched bench-to-bedside expertise to catalyze the adoption of precision medicine\nSAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ:ILMN) announced today the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer (CMO), starting March 26, 2018. In his new role, Dr. Febbo will be responsible for developing and executing on the Company’s medical strategy to drive genomic testing into healthcare practice.\nThis press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180312006000/en/\nIllumina names Dr. Phil Febbo Chief Medical Officer - Brings unmatched bench-to-bedside expertise to catalyze the adoption of precision medicine. (Photo: Business Wire)\n“We are very excited to welcome Dr. Febbo, who comes to us at a transformative time in the evolution of genomic medicine,” said Garret Hampton, Ph.D., Executive Vice President of Clinical Genomics at Illumina. “Phil brings a wealth of clinical and scientific experience to Illumina, from understanding the genomic basis of common human cancers, to the development of clinical tests based on next generation sequencing. We believe that his experience will ensure that Illumina is uniquely positioned to change medical practice with the use of genomics.”\nFor the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.\nDr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women’s Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.\nAbout Illumina\nIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.\nUse of forward-looking statements\nThis release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, and to deploy new products, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180312006000/en/\nIllumina, Inc.\nInvestors:\nJacquie Ross, CFA\n858-882-2172\nIR@illumina.com\nor\nMedia:\nLisa Warshaw\n323-360-8778\nPR@illumina.com\nSource: Illumina, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.illumina.com&esheet=51771520&newsitemid=20180312006000&lan=en-US&anchor=Illumina%2C+Inc.&index=1&md5=c219924cc4f7298eab13db0ae0832795", "http://www.businesswire.com/news/home/20180312006000/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.illumina.com&esheet=51771520&newsitemid=20180312006000&lan=en-US&anchor=www.illumina.com&index=2&md5=a57302bb89f322dd7f5ead9f7050a31f"], "published": "2018-03-12T23:05:00.000+02:00", "crawled": "2018-03-12T23:53:51.000+02:00", "highlightTitle": ""}